APAC Bioprocessing Facilities Market Trends This 2021
- 36% of all bioprocessing facilities in the Asia Pacific are engaged in the manufacturing of novel monoclonal antibodies.
- More than 40% of the manufacturing facilities in APAC have progressed from establishment to operations within the past 2 years.
- Biopharmaceutical companies in APAC are inclined towards adopting more process innovation technologies while expanding their facilities.
- Increased use of automation and artificial intelligence is driving the incorporation of single use systems, continuous bioprocessing, green initiatives, and alternative unit operations into facility design.
APAC’s biologics industry has seen impressive growth and is on an upward trajectory with the increase in demand for further innovation in bioprocessing technologies that reduce cost, maintain high quality and increase efficiency. Based on the data-driven analysis by IMAPAC, 36% of bioprocessing facilities in the Asia Pacific are engaged in the manufacturing of monoclonal antibodies followed by 16% involved in the vaccines and biosimilars manufacturing in the region. In addition, more than 40% of the manufacturing facilities in APAC have progressed from establishment to operations within the past 2 years. A prime case study points to the Flexfactory established by Cytiva in less than 18 months of period.
To meet the world’s demand for biologics drugs, more biopharmaceutical facilities are being built in Asia and manufacturing capacity is being expanded. In recent news, Cytiva, with China’s Wego Pharmaceutical Co Ltd, will be improving their manufacturing resilience with newly added manufacturing lines. This will triple the supply capacity of their single use consumables in the APAC region, enabling shorter lead times while maintaining high quality of their products.
To facilitate expansion plans, biopharmaceutical companies in APAC are inclined towards adopting more process innovation technologies in their biomanufacturing facilities, according to a study by IMAPAC. In particular, there is need for process chromatography, particularly during scale-up in downstream processing. In hopes of reducing bottlenecks, biopharmaceutical manufacturers are seeking to improve downstream recovery and reduce the cost per gram of protein produced, thereby positively impacting ultimate process yield for target biologics drug products.
Speaking of technologies, green initiatives, and alternative unit operations are being incorporated in facility design. This push is spurred by the rise in automation and artificial intelligence, which in turn affect installation, operational, and performance qualification (IQ, OQ, and PQ) activities. Single use technologies are not new to the industry and continues to rise in adoption. APAC biopharmaceutical experts surveyed by IMAPAC recently indicated a preferred adoption of large-scale single-use bioreactors to optimize quality and cost of production. The industry is also seeing accelerated adoption of continuous flow systems, partly due to the COVID-19 pandemic. However, the current bottlenecks include defining continuous processes and aligning the available equipment to operate as per current GMP requirements. These make achieving an end-to-end bioproduction line difficult.
The APAC facilities of Chugai Pharmaceutical, Hanmi Pharmaceutical, Daiichi Sankyo, Biocon, AlphaMab Oncology, BeiGene, Innovent Biologics and more are adapting to the fast-changing needs of the biologics industry. Incorporating more sophisticated systems and adopting smart, modular and flexible biopharmaceutical facilities enable biopharmaceutical companies a competitive edge in the medicines of tomorrow. The industry can expect a rise in opportunities for both biopharmaceutical innovators and technology providers riding on the wave of these trends.
This article is brought to you by IMAPAC’s market research team. For more on the details of the APAC Bioprocessing sector, check our Market Reports or Dashboards.